Tenders/INFLIXIMAB IV

INFLIXIMAB IV

IMELDA VZW

Published: Nov 3, 2026

Updated: Nov 9, 2026

About This Opportunity

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Belgium, Europe, this opportunity is open to firms and consortiums.

Published through Belgium e-Procurement, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. Interested parties should review the full documentation on the original source before submitting their proposal.

Description

Auto-translated from Dutch

This tender, originating from Belgium and sourced via belgium_eprocurement, seeks the supply of Infliximab IV. Infliximab is a crucial medication used in the treatment of various autoimmune diseases, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. The procurement authority is looking for qualified suppliers capable of consistently providing this biologic therapy, adhering to stringent quality and safety standards. Typical requirements for such a tender would include evidence of regulatory approval (e.g., EMA marketing authorization), robust supply chain management to ensure product integrity and timely delivery, and adherence to Good Distribution Practices (GDP). Bidders may be expected to provide detailed product information, including manufacturing processes, quality control measures, and storage and handling instructions. Furthermore, the tender will likely specify packaging requirements, shelf-life expectations, and potentially post-market surveillance commitments. The contracting authority will assess bids based on factors such as price, reliability of supply, quality assurance, and the supplier's capacity to meet demand. Experience in supplying similar pharmaceutical products to healthcare institutions in the European Union will likely be a significant advantage for prospective bidders.

Data provenance

This notice is sourced from Belgium e-Procurement and was originally published on November 3, 2026. Last refreshed today. Original language: Dutch. BidsFactory mirrors official procurement notices and links back to the source for full legal text.

About IMELDA VZW

IMELDA VZW has issued 8 procurement notices on BidsFactory, including 1 currently open and 0 awarded contracts. Activity concentrates in Health & Medical, Research & Innovation, and Agriculture & Food Security. All notices are published for Belgium. Notices are distributed via Belgium e-Procurement. Most recent publication: November 3, 2026.

Frequently asked questions about this tender

What type of contract is this?

This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.

Where will the contract be performed?

The contract is for delivery in Belgium. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.

How can I submit a bid?

Visit Belgium e-Procurement to access the full notice, required documents, and submission instructions provided by the contracting authority.

Who is the contracting authority?

This notice was issued by IMELDA VZW in Belgium. The authority is responsible for evaluating bids, awarding the contract, and managing performance.